Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Etienne Nichols
What’s the difference?
Liza Dzhezhora
How to ensure the integration of IoMT devices in your practice
Del Williams
Options to address the risk of combustible dust explosions for NFPA 61 compliance
Doug Folsom
Unpatched vulnerabilities will become increasingly susceptible to cyberattacks
Del Williams
Mitigate risk, prevent safety issues by utilizing closed conveyor systems designed with sanitation in mind

More Features

FDA Compliance News
Creates one of the most comprehensive regulatory SaaS platforms for the industry
Company’s first funding round will be used to accelerate product development for its QMS and MES SaaS offerings
Showcasing tech, solutions, and services at Gulfood Manufacturing 2022
Easy, reliable leak testing with methylene blue
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity
First trial module of learning tool focuses on ISO 9001 and is available now
Free education source for global medical device community

More News

Quality Digest

FDA Compliance

i3 Announces Global Expansion

Published: Wednesday, December 20, 2006 - 23:00

Pharmaceutical services company i3 has entered the next phase of its global expansion which includes organic and acquired growth in India, Latin America and Europe.

Coupled with acquisitions in Canada and Asia Pacific that i3 made earlier this year, the additions will help i3’s pharmaceutical clients bring high-quality, well-tested drugs to market faster and cheaper.

i3’s Latin American expansion is due to its acquisition of one of the region’s largest privately held contract research organizations, which has operations in Argentina, Brazil, Costa Rica, Mexico, Peru and Uruguay. Its expansion in India includes the opening of a full service office in Delhi, which will provide clinical research and data services for India-specific and global drug trials. New offices in Poland and expanded offices in France and the United Kingdom will boost the company’s European presence.

“Our strategy of increased geographic reach continues to honor i3’s responsibility to our customers,” says Glenn Bilawsky, i3’s CEO. “Pharmaceutical companies want to expedite development and gain cost efficiencies through well-run trials that are completed on time and on budget. Our expansion will help us accomplish those goals while still maintaining i3’s commitment to specialization and quality, which has become an industry hallmark.”

For more information, visit www.i3global.com/en/press/Press_release_i3globalexpansion.pdf.


About The Author

Quality Digest’s picture

Quality Digest

For 40 years Quality Digest has been the go-to source for all things quality. Our newsletter, Quality Digest, shares expert commentary and relevant industry resources to assist our readers in their quest for continuous improvement. Our website includes every column and article from the newsletter since May 2009 as well as back issues of Quality Digest magazine to August 1995. We are committed to promoting a view wherein quality is not a niche, but an integral part of every phase of manufacturing and services.